Pub Date : 2023-12-06DOI: 10.34172/jrip.2023.32150
N. Shamspour, Zeinab Jafarian, Maryam Alsadat Mousavi, H. Ahmadipour, Jalal Azmandian
Introduction: Peritonitis is a cause of mortality among peritoneal dialysis (PD) patients. Some studies suggested that uric acid (UC) levels may be effective in inflammatory processes. Objectives: We have examined the relationship between serum UC and peritonitis in PD patients. Patients and Methods: A retrospective cohort study was conducted over six years. The statistical population was all PD patients who underwent PD for at least six months. The sample size included 151 patients based on serum UC levels (less than or equal to 6.5 mg/dL, more than 6.5 mg/dL) and was divided into two groups. Both groups were compared using inflammatory factors and peritonitis. Results: In total, around 100 patients (66.2%) had UC levels ≤6.5 mg/dL, and 51 patients (33.7%) had serum UC levels >6.5 mg/dL. Peritonitis was observed in 72 (47.6%) patients. The frequency of peritonitis in the patients with greater levels of serum UC (51%) was higher compared to the other group (46%), but this difference was not statistically significant (P=0.56). The average hemoglobin level was lower in higher serum UC levels group (P=0.002). The mean levels of serum albumin (P=0.002), phosphorus (P=0.004), and creatinine (P=0.02) were lower in the group with serum UC below 6.5 mg/dL group. Conclusion: There was no correlation discovered between peritonitis and serum UC levels. However, it seems that serum UC can serve as a marker among PD patients to predict the occurrence of anemia and malnutrition.
{"title":"Relationship between the level of uric acid and peritonitis in peritoneal dialysis patients; a retrospective cohort study","authors":"N. Shamspour, Zeinab Jafarian, Maryam Alsadat Mousavi, H. Ahmadipour, Jalal Azmandian","doi":"10.34172/jrip.2023.32150","DOIUrl":"https://doi.org/10.34172/jrip.2023.32150","url":null,"abstract":"Introduction: Peritonitis is a cause of mortality among peritoneal dialysis (PD) patients. Some studies suggested that uric acid (UC) levels may be effective in inflammatory processes. Objectives: We have examined the relationship between serum UC and peritonitis in PD patients. Patients and Methods: A retrospective cohort study was conducted over six years. The statistical population was all PD patients who underwent PD for at least six months. The sample size included 151 patients based on serum UC levels (less than or equal to 6.5 mg/dL, more than 6.5 mg/dL) and was divided into two groups. Both groups were compared using inflammatory factors and peritonitis. Results: In total, around 100 patients (66.2%) had UC levels ≤6.5 mg/dL, and 51 patients (33.7%) had serum UC levels >6.5 mg/dL. Peritonitis was observed in 72 (47.6%) patients. The frequency of peritonitis in the patients with greater levels of serum UC (51%) was higher compared to the other group (46%), but this difference was not statistically significant (P=0.56). The average hemoglobin level was lower in higher serum UC levels group (P=0.002). The mean levels of serum albumin (P=0.002), phosphorus (P=0.004), and creatinine (P=0.02) were lower in the group with serum UC below 6.5 mg/dL group. Conclusion: There was no correlation discovered between peritonitis and serum UC levels. However, it seems that serum UC can serve as a marker among PD patients to predict the occurrence of anemia and malnutrition.","PeriodicalId":16950,"journal":{"name":"Journal of Renal Injury Prevention","volume":"29 3","pages":""},"PeriodicalIF":0.7,"publicationDate":"2023-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138596408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Computed tomography (CT) is a key method for various disorders. Image can be more quality with intravenous contrast media, however in some cases may be accompanied by a risk of kidney impairment. Objectives: This study aimed to investigate the association between acute kidney injury incidence and intravenous contrast media for CT in emergency patients. Methods and Materials: Search strategies were performed using standard keywords across international databases such as Web of Science, Scopus, Cochrane, PubMed, and Embase. Dimension, OpenGrey, DOAJ, CINAHL, and Google Scholar search engines were searched for a complete search. Additionally, manual searching was conducted using the references of related articles. Studies that reported the correlation between acute kidney injury incidence and intravenous contrast media were included in this systematic review. Results: First, 1185 studies were identified. After duplication, 533 studies remained and 417 were excluded. Out of 116 evaluated studies for retrieval, 49 were eliminated and 67 were assessed for eligibility. Ultimately, 28 studies with 48878 patients were included in the final review. Most of the studies were retrospective cohorts and have found no significant correlation between the incidence of acute kidney injury and intravenous contrast media administration (ICMA) for CT. Conclusion: Intravenous contrast media with a conventional dose for CT does not cause acute kidney injury unless in the presence of a particular condition. Registration: This study was compiled following the PRISMA checklist and its protocol was registered on the PROSPERO (CRD42023448461) and Research Registry (UIN: reviewregistry1690) websites.
计算机断层扫描(CT)是治疗各种疾病的关键方法。静脉造影剂可以提高图像质量，但在某些情况下可能伴有肾脏损害的风险。目的:本研究旨在探讨急诊患者急性肾损伤发生率与静脉CT造影剂的关系。方法和材料:使用国际数据库(如Web of Science、Scopus、Cochrane、PubMed和Embase)中的标准关键词执行搜索策略。对Dimension、OpenGrey、DOAJ、CINAHL和Google Scholar搜索引擎进行了完整的搜索。并利用相关文献的参考文献进行人工检索。报道急性肾损伤发生率与静脉造影剂相关性的研究被纳入本系统综述。结果:首先，确定了1185项研究。重复后，533项研究被保留，417项被排除。在116项被评估的研究中，49项被淘汰，67项被评估为合格。最终，28项研究共48878例患者被纳入最终综述。大多数研究都是回顾性队列，并没有发现急性肾损伤发生率与CT静脉造影剂给药(ICMA)之间的显著相关性。结论:常规剂量的CT静脉造影剂不会引起急性肾损伤，除非有特殊情况。注册:本研究按照PRISMA清单进行编制，其方案已在PROSPERO (CRD42023448461)和Research Registry (UIN: reviewregistry1690)网站上注册。
{"title":"Contrast-associated acute kidney injury following intravenous contrast media computed tomography; new concept and future directions: A systematic review study on emergencies patients","authors":"Hamidreza Khodabandeh, Arash Izadpanah Ghahremani, Ali Zolfi gol, Negar Jafari, Hussein Soleimantabar, Venus Shahabi Rabori, Hanie Fooladi, Fariba Asadi Noghabi, Ali Erfani, Reza Faramarzzadeh","doi":"10.34172/jrip.2023.32234","DOIUrl":"https://doi.org/10.34172/jrip.2023.32234","url":null,"abstract":"Introduction: Computed tomography (CT) is a key method for various disorders. Image can be more quality with intravenous contrast media, however in some cases may be accompanied by a risk of kidney impairment. Objectives: This study aimed to investigate the association between acute kidney injury incidence and intravenous contrast media for CT in emergency patients. Methods and Materials: Search strategies were performed using standard keywords across international databases such as Web of Science, Scopus, Cochrane, PubMed, and Embase. Dimension, OpenGrey, DOAJ, CINAHL, and Google Scholar search engines were searched for a complete search. Additionally, manual searching was conducted using the references of related articles. Studies that reported the correlation between acute kidney injury incidence and intravenous contrast media were included in this systematic review. Results: First, 1185 studies were identified. After duplication, 533 studies remained and 417 were excluded. Out of 116 evaluated studies for retrieval, 49 were eliminated and 67 were assessed for eligibility. Ultimately, 28 studies with 48878 patients were included in the final review. Most of the studies were retrospective cohorts and have found no significant correlation between the incidence of acute kidney injury and intravenous contrast media administration (ICMA) for CT. Conclusion: Intravenous contrast media with a conventional dose for CT does not cause acute kidney injury unless in the presence of a particular condition. Registration: This study was compiled following the PRISMA checklist and its protocol was registered on the PROSPERO (CRD42023448461) and Research Registry (UIN: reviewregistry1690) websites.","PeriodicalId":16950,"journal":{"name":"Journal of Renal Injury Prevention","volume":"34 23","pages":""},"PeriodicalIF":0.7,"publicationDate":"2023-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138601396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-04DOI: 10.34172/jrip.2023.32248
Elham Saffarieh, F. Nokhostin, Azadeh Yousefnezhad, Seyedeh Reyhaneh Yousefi Sharemi
Cancer-associated thrombotic microangiopathy (TMA) is a rare but is a serious complication that can occur in individuals with malignancy. It is characterized by widespread small blood vessel thrombosis (formation of blood clots) in various organs of the body, leading to organ damage and dysfunction. The exact mechanisms underlying cancer-associated TMA are not fully understood. However, several factors may contribute to its development. Cancer cells can release procoagulant substances that promote blood clot formation, since some tumors can directly invade blood vessels, leading to endothelial cell damage and activation of the coagulation system. Additionally, certain chemotherapeutic agents used in cancer treatment can have adverse effects on the endothelium, further increasing the risk of TMA. Clinically, cancer-associated TMA presents with a range of symptoms depending on the organs affected. Common manifestations include microangiopathic hemolytic anemia, thrombocytopenia, and organ-specific symptoms such as neurological deficits, renal dysfunction, or cardiac abnormalities.
{"title":"Cancer-associated thrombotic microangiopathy; a review article","authors":"Elham Saffarieh, F. Nokhostin, Azadeh Yousefnezhad, Seyedeh Reyhaneh Yousefi Sharemi","doi":"10.34172/jrip.2023.32248","DOIUrl":"https://doi.org/10.34172/jrip.2023.32248","url":null,"abstract":"Cancer-associated thrombotic microangiopathy (TMA) is a rare but is a serious complication that can occur in individuals with malignancy. It is characterized by widespread small blood vessel thrombosis (formation of blood clots) in various organs of the body, leading to organ damage and dysfunction. The exact mechanisms underlying cancer-associated TMA are not fully understood. However, several factors may contribute to its development. Cancer cells can release procoagulant substances that promote blood clot formation, since some tumors can directly invade blood vessels, leading to endothelial cell damage and activation of the coagulation system. Additionally, certain chemotherapeutic agents used in cancer treatment can have adverse effects on the endothelium, further increasing the risk of TMA. Clinically, cancer-associated TMA presents with a range of symptoms depending on the organs affected. Common manifestations include microangiopathic hemolytic anemia, thrombocytopenia, and organ-specific symptoms such as neurological deficits, renal dysfunction, or cardiac abnormalities.","PeriodicalId":16950,"journal":{"name":"Journal of Renal Injury Prevention","volume":"71 16","pages":""},"PeriodicalIF":0.7,"publicationDate":"2023-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138604514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-04DOI: 10.34172/jrip.2023.32185
Neda Sadat Ahmadi, H. Samimagham, Mehdi Hassaniazad, Fatemeh Khajavi-Mayvan, MohammadHosein Sheybani-Arani, Ali Salimi Asl, Mitra Kazemi Jahromi
Introduction: In December 2019, the first clinical signs of patients infected with SARS CoV 2 surfaced, then the fatality rate rose daily with no available definitive therapy. Objectives: Considering the necessity for more research into plasma therapy, the urgency of treating patients with a severe disease, and the lack of comparable studies, we compared the effectiveness of hyperimmune plasma and plasmapheresis in COVID-19 patients. Patients and Methods: In this quasi-experimental study, 38 patients with severe COVID-19 were enrolled in two groups of 19 individuals treated with plasmapheresis and hyperimmune plasma after matching for severity. The researcher documented the patient’s information on a checklist submitted for statistical analysis using the SPSS software. Results: Patients comprised 60.53% of men and 39.5% of women. In this study, 60.53% of patients had underlying conditions, including hypertension and diabetes. The mean length of hospitalization for patients in the hyperimmune plasma group was considerably shorter than those in the plasmapheresis group (P<0.05). Conclusion: The average hospitalization time for patients who received hyperimmune plasma was considerably shorter than the plasmapheresis group. As a result, patients are encouraged to utilize this type of plasma at the earliest stages of the condition.
{"title":"Comparing the effectiveness of hyperimmune plasma and plasmapheresis in COVID-19 patients","authors":"Neda Sadat Ahmadi, H. Samimagham, Mehdi Hassaniazad, Fatemeh Khajavi-Mayvan, MohammadHosein Sheybani-Arani, Ali Salimi Asl, Mitra Kazemi Jahromi","doi":"10.34172/jrip.2023.32185","DOIUrl":"https://doi.org/10.34172/jrip.2023.32185","url":null,"abstract":"Introduction: In December 2019, the first clinical signs of patients infected with SARS CoV 2 surfaced, then the fatality rate rose daily with no available definitive therapy. Objectives: Considering the necessity for more research into plasma therapy, the urgency of treating patients with a severe disease, and the lack of comparable studies, we compared the effectiveness of hyperimmune plasma and plasmapheresis in COVID-19 patients. Patients and Methods: In this quasi-experimental study, 38 patients with severe COVID-19 were enrolled in two groups of 19 individuals treated with plasmapheresis and hyperimmune plasma after matching for severity. The researcher documented the patient’s information on a checklist submitted for statistical analysis using the SPSS software. Results: Patients comprised 60.53% of men and 39.5% of women. In this study, 60.53% of patients had underlying conditions, including hypertension and diabetes. The mean length of hospitalization for patients in the hyperimmune plasma group was considerably shorter than those in the plasmapheresis group (P<0.05). Conclusion: The average hospitalization time for patients who received hyperimmune plasma was considerably shorter than the plasmapheresis group. As a result, patients are encouraged to utilize this type of plasma at the earliest stages of the condition.","PeriodicalId":16950,"journal":{"name":"Journal of Renal Injury Prevention","volume":"27 6","pages":""},"PeriodicalIF":0.7,"publicationDate":"2023-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138602622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-04DOI: 10.34172/jrip.2023.32227
Abdul Mubdi AA Karim, H. Kasim, A. Albaar, Sitti Rabiul Zatalia Ramadhan, Nasrum Machmud, H. Rasyid, Pendrik Tandean, S. Bakri, Erwin Arief, Tutik Harjianti, R. Halim, A. Seweng
Introduction: Hyperphosphatemia in chronic kidney disease (CKD) patients can stimulate the production of the fibroblast growth factor-23 (FGF-23) phosphatonin hormone, which is associated with cardiac remodeling resulting in left ventricular hypertrophy (LVH). Objectives: To determine the correlation between FGF-23 level and LVH incidence in CKD patients and establish the associated risk factors. Materials and Methods: This cross-sectional study involved 74 CKD patients who were classified as stage 3 (n=18), stage 4 (n=17), stage 3 (n=18), dialysis stage 5 (n=20), or non-dialysis stage 5 (n=19). The FGF-23 levels of the patients were measured using the ELISA (enzyme-linked immunosorbent assay) kit method, whereas a cardiologist verified LVH using an echocardiographic examination based on the LVH criteria of >95 g/m2 for females and >115 g/m2 for males. Results: A significant difference was observed in the mean FGF-23 values between the LVH and non-LVH patients (443.27±437.047 RU/mL and 172.68±185.56 RU/mL, respectively; P<0.05). The receiver operating characteristics revealed that patients with FGF-23 levels >123.95 RU/mL had a 3.6 times greater risk of LVH compared to those with values ≤123.95 RU/mL. The LVH risk factors of gender and age, as well as hypertension, diabetes mellitus, and obesity diagnoses were not associated with LVH incidence in CKD patients. Conclusion: A significant association was found between FGF-23 level and LVH incidence in CKD patients, in which an FGF-23 level >123.95 RU/mL corresponded to a 3.6 times greater risk of LVH than those with FGF-23 levels below this value.
{"title":"The correlation between serum fibroblast growth factor-23 levels and left ventricular hypertrophy in chronic kidney disease patients","authors":"Abdul Mubdi AA Karim, H. Kasim, A. Albaar, Sitti Rabiul Zatalia Ramadhan, Nasrum Machmud, H. Rasyid, Pendrik Tandean, S. Bakri, Erwin Arief, Tutik Harjianti, R. Halim, A. Seweng","doi":"10.34172/jrip.2023.32227","DOIUrl":"https://doi.org/10.34172/jrip.2023.32227","url":null,"abstract":"Introduction: Hyperphosphatemia in chronic kidney disease (CKD) patients can stimulate the production of the fibroblast growth factor-23 (FGF-23) phosphatonin hormone, which is associated with cardiac remodeling resulting in left ventricular hypertrophy (LVH). Objectives: To determine the correlation between FGF-23 level and LVH incidence in CKD patients and establish the associated risk factors. Materials and Methods: This cross-sectional study involved 74 CKD patients who were classified as stage 3 (n=18), stage 4 (n=17), stage 3 (n=18), dialysis stage 5 (n=20), or non-dialysis stage 5 (n=19). The FGF-23 levels of the patients were measured using the ELISA (enzyme-linked immunosorbent assay) kit method, whereas a cardiologist verified LVH using an echocardiographic examination based on the LVH criteria of >95 g/m2 for females and >115 g/m2 for males. Results: A significant difference was observed in the mean FGF-23 values between the LVH and non-LVH patients (443.27±437.047 RU/mL and 172.68±185.56 RU/mL, respectively; P<0.05). The receiver operating characteristics revealed that patients with FGF-23 levels >123.95 RU/mL had a 3.6 times greater risk of LVH compared to those with values ≤123.95 RU/mL. The LVH risk factors of gender and age, as well as hypertension, diabetes mellitus, and obesity diagnoses were not associated with LVH incidence in CKD patients. Conclusion: A significant association was found between FGF-23 level and LVH incidence in CKD patients, in which an FGF-23 level >123.95 RU/mL corresponded to a 3.6 times greater risk of LVH than those with FGF-23 levels below this value.","PeriodicalId":16950,"journal":{"name":"Journal of Renal Injury Prevention","volume":"69 13","pages":""},"PeriodicalIF":0.7,"publicationDate":"2023-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138604845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Population categories based on income levels are frequently utilized to compare cancer rates across various countries. It is a valuable tool for assessing global health and helps to classify cancers and measure the incidence and mortality of different types of cancer. Objectives: This study aimed to evaluate global kidney cancer incidence and mortality rates in 2020 according to population category by income levels, using an ecological study design. Methods and Materials: This ecological study examines the correlation between the incidence and mortality of kidney cancer in 2020, reported by the GLOBOCAN project, since the population category by income levels was reported by the World Bank report. The linear regression method was conducted to assess this correlation. Results: Results demonstrated that the global incidence and mortality rate of kidney cancer in 2020 was estimated at 431288 and 179368 cases, respectively. The incidence and mortality rate of kidney cancer were higher in high-income countries, and both rates tend to be higher in more developed regions. However, there was no statistically significant correlation between the population category by income levels and kidney cancer incidence and mortality based on both crude rate (CR) and age-standardized rate (ASR) indicators (P>0.05). Conclusion: We conclude that incidence and mortality rates of kidney cancer are not associated with population category by income level.
{"title":"Assessing global kidney cancer incidence and mortality rates according to population category by income levels in 2020: An ecological study","authors":"Soleyman Alivand, Farinaz Fattahi, Zahra Zarei, M. Hosseinifard, Atieh Nouralishahi, Hakimeh Karimi Aliabadi, Simin Soltani Nejad, Noorbakhsh Alivand, Hanieh Molaee, Anna Ghorbani Doshantapeh","doi":"10.34172/jrip.2023.32243","DOIUrl":"https://doi.org/10.34172/jrip.2023.32243","url":null,"abstract":"Introduction: Population categories based on income levels are frequently utilized to compare cancer rates across various countries. It is a valuable tool for assessing global health and helps to classify cancers and measure the incidence and mortality of different types of cancer. Objectives: This study aimed to evaluate global kidney cancer incidence and mortality rates in 2020 according to population category by income levels, using an ecological study design. Methods and Materials: This ecological study examines the correlation between the incidence and mortality of kidney cancer in 2020, reported by the GLOBOCAN project, since the population category by income levels was reported by the World Bank report. The linear regression method was conducted to assess this correlation. Results: Results demonstrated that the global incidence and mortality rate of kidney cancer in 2020 was estimated at 431288 and 179368 cases, respectively. The incidence and mortality rate of kidney cancer were higher in high-income countries, and both rates tend to be higher in more developed regions. However, there was no statistically significant correlation between the population category by income levels and kidney cancer incidence and mortality based on both crude rate (CR) and age-standardized rate (ASR) indicators (P>0.05). Conclusion: We conclude that incidence and mortality rates of kidney cancer are not associated with population category by income level.","PeriodicalId":16950,"journal":{"name":"Journal of Renal Injury Prevention","volume":"78 2","pages":""},"PeriodicalIF":0.7,"publicationDate":"2023-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139262517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Portulaca oleracea, or purslane, is a medicinal plant used in traditional medicine, according to its various medical properties, as well as its potential antioxidant and anti-inflammatory properties. Objectives: The present study aimed to investigate the efficacy of P. oleracea powder on 24-hour urine indices in patients with nephrolithiasis and normal kidney function. Patients and Methods: In this randomized clinical trial, eligible patients with nephrolithiasis were randomly assigned to receive P. oleracea or placebo capsules once daily for eight weeks. Twenty-four-hour urine indices, along with serum electrolytes, inflammatory and lipid components were measured, then compared between the two groups at baseline and the end of the trial. Results: A total of 54 patients, including 28 in P. oleracea and 26 in the control groups, were assigned. Their mean age was 42.2±9.8 years; there was no statistically significant difference between the mean age of the P. oleracea and placebo groups (42.1years versus 42.2 years, respectively; P>0.05). After eight weeks, the mean urine citrate level in the Portulaca oleracea subjects (674.82±94.56 mg/24 h) was significantly higher than placebo group subjects (579.19±85.06 mg/24 h; P<0.01). In addition, the mean urine calcium level in the P. oleracea group (176.32±27.40 mg/24 h) was significantly lower compared to the control group (194.26±25.17 mg/24 h; P=0.016). Within the groups, analysis revealed that in subjects in P. oleracea and control groups, mean serum triglyceride (TG) decreased after intervention (P=0.01 and P=0.02, respectively), as well as mean urine citrate level (P<0.01, P=0.01, respectively). Conclusion: The findings show that P. oleracea may be proposed as a medicinal plant that has a preventive effect on kidney stone formation by increasing urine citrate and decreasing urine calcium level. Trial Registration: The trial protocol was approved by the Iranian Registry of Clinical Trials (identifier: IRCT20170725035305N4; https://en.irct.ir/trial/42388, ethical code; IR.SBMU.MSP. REC.1398.538).
{"title":"The effects of <i>Portulaca oleracea</i> extract on 24-hour urine indices in patients with renal stone: A double-blind randomized placebo-controlled clinical trial","authors":"Amirhesam Alirezaei, Kimia Karimi Toudeshki, Seyed Behnaz Nouri, Seyed Amirhossein Fazeli, Firoze Hatami, Amirhossein Miladipour, Seyed Pedram Montazeri-Ghominezhad","doi":"10.34172/jrip.2023.32240","DOIUrl":"https://doi.org/10.34172/jrip.2023.32240","url":null,"abstract":"Introduction: Portulaca oleracea, or purslane, is a medicinal plant used in traditional medicine, according to its various medical properties, as well as its potential antioxidant and anti-inflammatory properties. Objectives: The present study aimed to investigate the efficacy of P. oleracea powder on 24-hour urine indices in patients with nephrolithiasis and normal kidney function. Patients and Methods: In this randomized clinical trial, eligible patients with nephrolithiasis were randomly assigned to receive P. oleracea or placebo capsules once daily for eight weeks. Twenty-four-hour urine indices, along with serum electrolytes, inflammatory and lipid components were measured, then compared between the two groups at baseline and the end of the trial. Results: A total of 54 patients, including 28 in P. oleracea and 26 in the control groups, were assigned. Their mean age was 42.2±9.8 years; there was no statistically significant difference between the mean age of the P. oleracea and placebo groups (42.1years versus 42.2 years, respectively; P>0.05). After eight weeks, the mean urine citrate level in the Portulaca oleracea subjects (674.82±94.56 mg/24 h) was significantly higher than placebo group subjects (579.19±85.06 mg/24 h; P<0.01). In addition, the mean urine calcium level in the P. oleracea group (176.32±27.40 mg/24 h) was significantly lower compared to the control group (194.26±25.17 mg/24 h; P=0.016). Within the groups, analysis revealed that in subjects in P. oleracea and control groups, mean serum triglyceride (TG) decreased after intervention (P=0.01 and P=0.02, respectively), as well as mean urine citrate level (P<0.01, P=0.01, respectively). Conclusion: The findings show that P. oleracea may be proposed as a medicinal plant that has a preventive effect on kidney stone formation by increasing urine citrate and decreasing urine calcium level. Trial Registration: The trial protocol was approved by the Iranian Registry of Clinical Trials (identifier: IRCT20170725035305N4; https://en.irct.ir/trial/42388, ethical code; IR.SBMU.MSP. REC.1398.538).","PeriodicalId":16950,"journal":{"name":"Journal of Renal Injury Prevention","volume":"99 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135901080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-02DOI: 10.34172/jrip.2023.32245
Parisa Keshtgar, Leila Mahmoodnia, Samin Karamian
Cisplatin-induced nephrotoxicity is a crucial concern in cancer patients, limiting the dose and duration of cisplatin therapy. Several mechanisms contribute to cisplatin nephrotoxicity, including oxidative stress, inflammation, and mitochondrial dysfunction. SGLT2 inhibitors have emerged as a promising therapeutic option for various renal disorders due to their ability to restore renal homeostasis and mitigate renal injury
{"title":"Possible amelioration impact of sodium-glucose cotransporter 2 inhibitors on cisplatin-induced renal toxicity; a mini-review on recent findings","authors":"Parisa Keshtgar, Leila Mahmoodnia, Samin Karamian","doi":"10.34172/jrip.2023.32245","DOIUrl":"https://doi.org/10.34172/jrip.2023.32245","url":null,"abstract":"Cisplatin-induced nephrotoxicity is a crucial concern in cancer patients, limiting the dose and duration of cisplatin therapy. Several mechanisms contribute to cisplatin nephrotoxicity, including oxidative stress, inflammation, and mitochondrial dysfunction. SGLT2 inhibitors have emerged as a promising therapeutic option for various renal disorders due to their ability to restore renal homeostasis and mitigate renal injury","PeriodicalId":16950,"journal":{"name":"Journal of Renal Injury Prevention","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135901077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Renal impairment is a common complication in patients with ovarian cancer. Renal impairment in ovarian cancer patients can be caused by various factors. Many of the chemotherapeutic agents administered to treat ovarian cancer are nephrotoxic and can promote kidney dysfunction, leading to renal impairment. Ovarian tumors can obstruct the urinary tract, leading to a reduction in renal function and dilation of the upper urinary tract. Acute kidney injury (AKI) can occur in ovarian cancer patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Women treated for epithelial ovarian cancer suffer an accelerated rate of renal function decline, independent of major risk factors for kidney disease. Conversely, renal impairment can affect the dosage of chemotherapy drugs used in ovarian cancer treatment. Dose reduction, dose adjustment based on pharmacokinetic data, alternative treatment regimens, and individualized dosing may be necessary to ensure optimal therapeutic outcomes while minimizing the risk of toxicity and treatment-related complications.
{"title":"Renal dysfunction in individuals with ovarian cancer; a review on current concepts","authors":"Azadeh Yousefnezhad, Seyedeh Reyhaneh Yousefi Sharemi, Elham Saffarieh, Fahimeh Nokhostin","doi":"10.34172/jrip.2023.32247","DOIUrl":"https://doi.org/10.34172/jrip.2023.32247","url":null,"abstract":"Renal impairment is a common complication in patients with ovarian cancer. Renal impairment in ovarian cancer patients can be caused by various factors. Many of the chemotherapeutic agents administered to treat ovarian cancer are nephrotoxic and can promote kidney dysfunction, leading to renal impairment. Ovarian tumors can obstruct the urinary tract, leading to a reduction in renal function and dilation of the upper urinary tract. Acute kidney injury (AKI) can occur in ovarian cancer patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Women treated for epithelial ovarian cancer suffer an accelerated rate of renal function decline, independent of major risk factors for kidney disease. Conversely, renal impairment can affect the dosage of chemotherapy drugs used in ovarian cancer treatment. Dose reduction, dose adjustment based on pharmacokinetic data, alternative treatment regimens, and individualized dosing may be necessary to ensure optimal therapeutic outcomes while minimizing the risk of toxicity and treatment-related complications.","PeriodicalId":16950,"journal":{"name":"Journal of Renal Injury Prevention","volume":"197 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135606590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-23DOI: 10.34172/jrip.2023.32222
Mahdi Maloomi, Ali Noursina, Maryam Omidi
Acute kidney injury (AKI) is a common clinical condition characterized by a rapid decline in renal function. AKI is associated with significant morbidity and mortality, and many patients with AKI develop chronic kidney disease (CKD). Previous studies have examined the association between AKI and CKD; however, the relationship between AKI types and CKD development has not been thoroughly investigated. Therefore, a multi-center prospective observational study is required to investigate this relationship thoroughly. These findings may have significant implications for the early identification, prevention, and management of CKD in patients with a history of AKI.
{"title":"Exploring the connection between types of acute kidney injury and chronic kidney disease","authors":"Mahdi Maloomi, Ali Noursina, Maryam Omidi","doi":"10.34172/jrip.2023.32222","DOIUrl":"https://doi.org/10.34172/jrip.2023.32222","url":null,"abstract":"Acute kidney injury (AKI) is a common clinical condition characterized by a rapid decline in renal function. AKI is associated with significant morbidity and mortality, and many patients with AKI develop chronic kidney disease (CKD). Previous studies have examined the association between AKI and CKD; however, the relationship between AKI types and CKD development has not been thoroughly investigated. Therefore, a multi-center prospective observational study is required to investigate this relationship thoroughly. These findings may have significant implications for the early identification, prevention, and management of CKD in patients with a history of AKI.","PeriodicalId":16950,"journal":{"name":"Journal of Renal Injury Prevention","volume":"14 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135966749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：